Ipsen re­cruits Steven Hilde­mann as CMO; Eli Lil­ly of­fers two more low-cost in­sulin op­tions

→ Af­ter los­ing their CEO last month, Ipsen — who’s grap­pling with an FDA hold af­ter safe­ty con­cerns emerged from late-stage stud­ies of its lead rare dis­ease drug palo­varotenehas tapped for­mer Mer­ck Serono ex­ec Steven Hilde­mann as EVP, chief med­ical of­fi­cer, head of glob­al med­ical af­fairs and phar­ma­covig­i­lance. Dur­ing his time at Mer­ck, Hilde­mann served as CMO and SVP and head of glob­al med­ical af­fairs and pa­tient safe­ty. His pre­vi­ous ex­pe­ri­ence spans Mer­ck/Scher­ing Plough, Am­gen and Pfiz­er/Phar­ma­cia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.